“The KREX™ technology is a continuously evolving platform. In the near future, I think we will realise my original vision of not only identifying new autoantibody biomarkers for precision immuno-profiling but also protective autoantibodies that may have enormous therapeutic potential.”
Professor Jonathan Blackburn
Chief Scientific Officer
Sengenics is a functional proteomics company that leverages its patented KREX™ technology for production of full-length, correctly folded and functional proteins. KREX™ was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge. Jonathan is the CSO of Sengenics.
The key application of KREX™ is the discovery of autoantibody biomarkers for two core medical use cases. Firstly, stratification of patients undergoing treatment with autoimmune or cancer drugs into responders, non-responders and those that may exhibit severe immune-related adverse events. Secondly, identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests.
Sengenics currently has commercial partnerships with 9 out of the top 20 pharma to co-develop complementary and companion diagnostic tests for autoimmune and cancer immunotherapy drugs. The company has commenced the process for obtaining FDA 510(k) approval for several of these tests and plans to launch them in 2020.
Sengenics is a proud member of the following consortia:
Sengenics is pursuing potential collaborators for early stage opportunities in order to identify and develop innovative products. Please contact us to arrange a discussion.
Sengenics is a privately held limited liability company that was established in 2008. The company’s primary incorporation is in the UK, Singapore and Malaysia. Current major institutional investors and shareholders include Soft Bank Investment, which is a subsidiary of Soft Bank Pharmaceuticals (SBI Holdings) in Japan; and Insas Technology, an investment holding and management company based in Singapore and Malaysia. Sengenics also has a fourth laboratory through a collaboration with the University of Cape Town in South Africa.
Sengenics is actively seeking strategic scientific and corporate partnerships to proliferate the use of its patented KREX proteomics technology. In addition, we are actively seeking opportunities for in-licensing of complementary technologies and out-licensing of Sengenics biomarker patents. Please contact us to arrange a discussion.
2008 – 2020© Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361